logo
Book a meeting
NeuroSense Therapeutics

Neuro Sense Therapeutics

Biotechnology, Cambridge, Massachusetts, United States, 11-50 Employees

neurosense-tx.com

  • facebook
  • twitter
  • instagram
  • LinkedIn

phone no Phone Number: 12***********

Who is NEUROSENSE THERAPEUTICS

Advancing research, development and therapy for ALS and additional CNS indications. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the develop...

Read More

lock icon Get Full Access
map
  • Cambridge, Massachusetts, United States Headquarters: Cambridge, Massachusetts, United States
  • 2017 Date Founded: 2017
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

checked-icon Does something look wrong? Fix it. | View contact records from NEUROSENSE THERAPEUTICS

NeuroSense Therapeutics Org Chart and Mapping

Employees
Ferenc Tracik

Ferenc Tracik

Chief Medical Officer

See Full Org Chart arrow
email-formate-icon
View Email Formats for NeuroSense Therapeutics
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding NeuroSense Therapeutics

Answer: NeuroSense Therapeutics's headquarters are located at Cambridge, Massachusetts, United States

Answer: NeuroSense Therapeutics's phone number is 12***********

Answer: NeuroSense Therapeutics's official website is https://neurosense-tx.com

Answer: NeuroSense Therapeutics's revenue is Under $1 Million

Answer: NeuroSense Therapeutics has 11-50 employees

Answer: NeuroSense Therapeutics is in Biotechnology

Answer: NeuroSense Therapeutics contact info: Phone number: 12*********** Website: https://neurosense-tx.com

Answer: Advancing research, development and therapy for ALS and additional CNS indications. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases. Currently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients globally.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access